Tag Archives: Novartis

Financial Daily Dose 7.2.2020 | Top Story: Resurgent virus threatens nascent US economic recovery

BY: Michael D. Reif | July 2, 2020

A resurgent virus is spelling trouble for the promised return of the American economy, with states seeing big Covid blooms now losing ground on the economic activity and hiring that helped propel markets to their best quarter since the late 1990s – NYTimes and WSJ and MarketWatch and Bloomberg We’ll be poring through the June … Continue reading

Financial Daily Dose 3.3.2020 | Top Story: Promised Central Bank Action Halts Market Slide (for now)

BY: Michael D. Reif | March 3, 2020

Despite news of additional COVID-19-related deaths and infections in America, central bankers appear to have bought at least one day of peace for US markets, which posted strong gains on a late surge on Monday, breaking a week straight of losses – NYTimes and WSJ and Bloomberg and MarketWatch That said, all remains far from … Continue reading

Financial Daily Dose 8.7.2019 | Top Story: Novartis Hid Altered Drug Test Data From FDA

BY: Michael D. Reif | August 7, 2019

A new report out Tuesday from the Food & Drug Administration reveals that drug maker Novartis “concealed manipulated data” from the agency “while applying for approval of an extremely expensive gene therapy treatment and then delayed reporting the issue.” Still, the FDA is keeping Zolgensma, the drug in question, on the market – NYTimes and … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | October 31, 2017

Soooo . . . . Financial news, anyone? Swiss pharma giant Novartis has issued a $3.9 billion cash bid to buy Advanced Accelerator Applications, a French company [and spinoff of the organization in charge of the Large Hadron Collider] known for producing tumor-treating drug Lutathera, among others – NYTimes Breakingviews thinks the deal should be … Continue reading